| Enhanced detection of circulating tumor DNA by fragment size analysis F Mouliere, D Chandrananda, AM Piskorz, EK Moore, J Morris, ... Science translational medicine 10 (466), eaat4921, 2018 | 846 | 2018 |
| Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial HSP Benedikte Hasselbalch, Ulrik Lassen, Steinbjørn Hansen, Mats Holmberg ... Neuro-oncology 12 (5), 508-516, 2010 | 274 | 2010 |
| First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF ... Clin Oncol 34 (34), 4142-4150, 2016 | 226* | 2016 |
| Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial JS De Bono, N Concin, DS Hong, FC Thistlethwaite, JP Machiels, ... The lancet oncology 20 (3), 383-393, 2019 | 163 | 2019 |
| Small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up M Sørensen, E Felip Annals of Oncology 20 (suppl_4), ii71-ii72, 2009 | 157* | 2009 |
| A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia R Garzon, M Savona, R Baz, M Andreeff, N Gabrail, M Gutierrez, L Savoie, ... Blood, The Journal of the American Society of Hematology 129 (24), 3165-3174, 2017 | 151 | 2017 |
| Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma J Kuruvilla, M Savona, R Baz, PM Mau-Sorensen, N Gabrail, R Garzon, ... Blood, The Journal of the American Society of Hematology 129 (24), 3175-3183, 2017 | 150 | 2017 |
| Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up M Sørensen, M Pijls-Johannesma, E Felip Annals of Oncology 21, v120-v125, 2010 | 137 | 2010 |
| Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia C Chen, D Siegel, M Gutierrez, M Jacoby, CC Hofmeister, N Gabrail, ... Blood 131 (8), 855-863, 2018 | 135 | 2018 |
| Bevacizumab plus irinotecan in the treatment of patients with progressive recurrent malignant brain tumours HS Poulsen, K Grunnet, M Sorensen, P Olsen, B Hasselbalch, ... Acta Oncologica 48, 52-58, 2009 | 131 | 2009 |
| In vitro cross-resistance and collateral sensitivity in seven resistant small cell lung cancer cell lines. Preclinical identification of suitable drug partners to taxotere … PB Jensen, B Holm, M Sorensen, IJ Christensen, M Sehested Br j Cancer 75, 869-877, 1997 | 130 | 1997 |
| Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis KG Spindler, AK Boysen, N Pallisgård, JS Johansen, J Tabernero, ... the oncologist 22 (9), 1049-1055, 2017 | 127 | 2017 |
| Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up G D'addario, E Felip Annals of oncology 19 (suppl_2), ii39-ii40, 2008 | 113 | 2008 |
| Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer LM Smyth, SA Piha-Paul, HH Won, AM Schram, C Saura, S Loi, J Lu, ... Cancer discovery 10 (2), 198-213, 2020 | 111 | 2020 |
| Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme U Lassen, M Sorensen, TB Gaziel, B Hasselbalch, HS Poulsen Anticancer Research 33, 1657-1660, 2013 | 111 | 2013 |
| Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi) D Hyman, S Kummar, A Farago, B Geoerger, M Mau-Sorensen, M Taylor, ... Cancer Research 79 (13_Supplement), CT127-CT127, 2019 | 106 | 2019 |
| A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients … U Lassen, LR Molife, M Sorensen, SA Engelholm, L Vidal, R Sinha, ... Br J Cancer, 29 (1), 12-17, 2010 | 97 | 2010 |
| Immunohistochemical detection of DNA topoisomerase II , P-glyco-protein and MultiDrug Resistance related protein (MRP) in small cell and non-small cell lung cancer J Kreisholt, M Sorensen, PB Jensen, BS Nielsen, CB Andersen, ... br j cancer 77, 1469-1473, 1998 | 92* | 1998 |
| A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours MTJ van Bussel, A Awada, MJA de Jonge, M Mau-Sørensen, D Nielsen, ... British Journal of Cancer 124 (4), 728-735, 2021 | 84 | 2021 |
| Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum resistant ovarian cancer Y Chen, C Camacho, TR Silvers, AR Razak, JF Gabrail, NY, Gerecitano, ... Clin Cancer Res 23, 1552-1563, 2017 | 81 | 2017 |
Ulrik Lassen, Professor, MD, PH.D.Phase 1 Unit, Department of Oncology在 regionh.dk 的电子邮件经过验证
